How JustAnswer Works:
  • Ask an Expert
    Experts are full of valuable knowledge and are ready to help with any question. Credentials confirmed by a Fortune 500 verification firm.
  • Get a Professional Answer
    Via email, text message, or notification as you wait on our site.
    Ask follow up questions if you need to.
  • 100% Satisfaction Guarantee
    Rate the answer you receive.
Ask khagihara Your Own Question
khagihara, Doctor
Category: Oncology
Satisfied Customers: 6590
Experience:  Trained in the multiple medical fields for many years.
Type Your Oncology Question Here...
khagihara is online now
A new question is answered every 9 seconds

My mother Mrs. Anita Kadam (Age 57) has been diagnosed with

Customer Question

Hello, my mother Mrs. Anita Kadam (Age 57) has been diagnosed with stage 4 Adenocarcinoma. She was having trouble breathing due to pleural fluid build-up. As per our oncologist's suggestion we have started Gemcitabine-Carboplatin chemotherapy on 29th Oct. Suggested course of treatment is 6 cycles of chemo. Because the test for EGFR mutations was not successful, doctors didn't suggest Erlotinib based treatment such as Tarceva. Can we switch to Erlotinib after two cycles of chemo without knowing whether EGFR is positive or not.
Submitted: 8 months ago.
Category: Oncology
Customer: replied 8 months ago.
Also can you please suggest any other course of treatment.
Expert:  khagihara replied 8 months ago.

There are no clinical trials that have established the optimal regimen for concurrent chemoradiotherapy. Widely used regimens include a full dose combination of cisplatin plus etoposide, in conjunction with once daily RT to a dose of approximately 60 Gy, which is followed by two additional cycles of cisplatin plus etoposide. An alternative “radiosensitizing chemotherapy” approach uses weekly carboplatin plus paclitaxel with approximately 60 Gy of radiation, follow by two cycles of consolidation with this same chemotherapy combination at standard doses. Agents that target the epidermal growth factor receptor (EGFR) pathway are being studied in combination with chemotherapy and radiotherapy for patients with unresectable stage III NSCLC. Targeted therapy is not indicated outside of a clinical trial for patients with unresectable stage III NSCLC.